The primary grounds for exclusion were interventions other than GLP-1 agonists, the inclusion of adult participants, participants with secondary causes of obesity, and participants with diabetes, unrelated to obesity. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.